News
-
-
PRESS RELEASE
Update on Ongoing Transactions with Pharmaceutical Company Grupo Landsteiner and the NASDAQ Listing of VERAXA Biotech AG
Xlife Sciences AG provides updates on ongoing transactions with Grupo Landsteiner and the NASDAQ listing of VERAXA Biotech AG, aiming to accelerate project development and corporate growth -
-
PRESS RELEASE
Xlife Sciences AG Announces Transition to the Main Segment of SIX Swiss Exchange to Strengthen Market Presence
Xlife Sciences AG announces transition to the main segment of SIX Swiss Exchange to strengthen market presence, with advantages like increased visibility, improved liquidity, and stronger recognition in capital markets -
-
PRESS RELEASE
Award-Winning Liver PET Tracer Highlights the Strength of Our Innovation Portfolio
Xlife Sciences AG announces the award-winning world's first liver-specific PET tracer, DAZAmed, highlighting scientific and commercial potential. A breakthrough in nuclear medicine for liver disease imaging -
-
PRESS RELEASE
Xlife Sciences AG Announces Exit of 12 Project Companies to Grupo Landsteiner and the Creation of a Scalable Transcontinental Life Sciences Platform
Xlife Sciences AG announces strategic exit of 12 projects to Grupo Landsteiner, forming a transcontinental life sciences platform with a NASDAQ listing in 2026 -
-
PRESS RELEASE
Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity
Xlife Sciences AG and saniva diagnostics GmbH announce NeuroMex, the world's first certified medical device for early Alzheimer's detection, with 83.5% accuracy in identifying early-stage Alzheimer's